Τόμος 32 (2018) – Τεύχος 3 –Άρθρο 6 – Review of Clinical Pharmacology and Pharmacokinetics – Διεθνής Έκδοση – Volume 32 (2018) – Issue 3 – Article 6 – Review of Clinical Pharmacology and Pharmacokinetics – International Edition

By | | Πλήρες Κείμενο στα Αγγλικά - Full Text in English
Τίτλος – Title

An Update on Medical Treatments for Neuroendocrine Tumors and their Rare Dermatologic Complications
Συγγραφέας – Author

Vasiliki-Sofia Grech MD

Physician. General Hospital Of Karpenisi, Karpenisi, Greece
Παραπομπή – Citation

V.-S. Grech. An Update on Medical Treatments for Neuroendocrine Tumors and their Rare Dermatologic Complications. Review Clin. Pharmacol. Pharmacokinet. 2018, 32, 3, 147-165
Ημερομηνία Δημοσιευσης – Publication Date
25-10-2018
Γλώσσα Πλήρους Κειμένου –
Full Text Language

Αγγλικά – English
Λέξεις κλειδιά – Keywords
Neuroendocrine tumors, dermatologic metastasis, medical therapy, therapeutic applications
Λοιποί Όροι – Other Terms

Μελέτη

Study
Περίληψη –Summary

Neuroendocrine tumours (NET’s), are a plethoric group of tumours with rare dermatologic complications by means of metastasis. These cases require prompt diagnosis as can modify chemotherapy protocols. Until recently, only a few therapeutic options for oncologic control of these tumors were available, mostly for highly graded NETs but with notable side effects. Since surgery is not a curative option for metastatic cases, other medical therapies have been developed. A number of pivot clinical trials have proven that low to intermediate NETs can be effectively controlled via targeted therapies. The PROMID study demonstrated that octreotide LAR can delay tumor growth in low grade midgut NETs, CLARINET study showed the benefits of lanreotide in grade 2 tumors in the gastrointestinal (GI) tract, RADIANT study established the immunosuppressant drug everolimus as an effective therapy for lung and GI NETs and SUN1111 trial recognized sunitinib as a therapy for the advanced pancreatic NETs. Furthermore, carcinoid syndrome therapy, arising from hormones and neuroamnies secreted NETs and prophylaxis from the carcinoid crisis are also discussed.

Ongoing and planned fundamental studies for targeted therapies in NETs may widen their therapeutic applications, while the development of rational combinations may further improve their therapeutic outcome. These successes and the improved understanding of the underlying genetic and immunologic background are likely to lead to further important advances on the horizon.
Αναφορές – References

Oberg, K., S. Jelic, and E.G.W. Group, Neuroendocrinegastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2008. 19 Suppl 2: ii104-5.

  1. Berber, E., N. Flesher, and A.E. Siperstein, Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg, 2002. 26(8): 985-90.
  2. Schnirer, II, J.C. Yao, and J.A. Ajani, Carcinoid–a comprehensive review. Acta Oncol, 2003. 42(7): 672-92.
  3. Kulke, M.H., et al., Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol, 2006. 24(3): 401-6.
  4. Strosberg, J.R., et al., First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 2011. 117(2): 268-75.
  5. Arnold, R., et al., Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol, 2005. 3(8): 761-71.
  6. Oberg, K., Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion, 2000. 62 Suppl 1: p. 92-7.
  7. Kulke, M.H., et al., Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol, 2017. 35(1): 14-23.
  8. Oberg, K.E., et al., Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology, 2010. 139(3): 742-53, 753 e1. 70.
  9. Susini, C. and L. Buscail, Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol, 2006. 17(12): 1733-42.
  10. Patel, Y.C., Somatostatin and its receptor family. Front Neuroendocrinol, 1999. 20(3): 157-98.
  11. Theodoropoulou, M. and G.K. Stalla, Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol, 2013. 34(3): 228-52.
  12. Garland, J., et al., Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther, 2003. 17(3): 437-44.
  13. Rinke, A., et al., Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol, 2009. 27(28): 4656-63.
  14. Caplin, M.E., et al., Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med, 2014. 371(3): 224-33.
  15. Ramage, J.K., et al., Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut, 2005. 54 Suppl 4: p. iv1-16
  16. Oberg, K.E., The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol (R Coll Radiol), 2012. 24(4): 282-93.
  17. Hofland, L.J., et al., Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J Endocrinol Invest, 2005. 28(11 Suppl International): 36-42.
  18. Xu, C. and H. Zhang, Somatostatin receptor based imaging and radionuclide therapy. Biomed Res Int, 2015. 2015: 917968.
  19. Giandomenico, V., C. Thirlwell, and M. Essand, Other Novel Therapies: Biomarkers, microRNAs and microRNA Inhibitors, DNA Methylation, Epigenetics, Immunotherapy and Virotherapy. Front Horm Res, 2015. 44: 248-62.
  20. Yao, J.C., et al., Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet, 2016. 387(10022): 968-77.
  21. Yao, J.C., et al., Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol, 2008. 26(26): 4311-8. 71
  22. Yao, J.C., et al., Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol, 2010. 28(1): 69-76.
  23. Pavel, M.E., et al., Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet, 2011. 378(9808): p. 2005-12.
  24. Wiedmann, M.W. and J. Mossner, Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors. Clin Med Insights Oncol, 2012. 6: 381-93.
  25. Kulke, M.H., et al., Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol, 2008. 26(20): 3403-10.
  26. Raymond, E., et al., Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med, 2011. 364(6): 501-13.
  27. Capozzi, M., et al., Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors. Anticancer Res, 2016. 36(10): 5025-5030.
  28. Berruti, A., et al., Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. BMC Cancer, 2014. 14: 184.
  29. Chan, J.A., et al., Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol, 2012. 30(24): 2963-8.
  30. Bruce, J.Y., et al., A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies. Cancer Chemother Pharmacol, 2014. 73(3): 485-93.
  31. Oberg, K., Which therapy for which patient? Future Medicine 2011: p. 64- 70.
  32. Oberg, K., et al., Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012. 23 Suppl 7: vii124-30
  33. Jones, P.A. and S.B. Baylin, The fundamental role of epigenetic events in cancer. Nat Rev Genet, 2002. 3(6): 415-28.
  34. Esteller, M., Epigenetics in cancer. N Engl J Med, 2008. 358(11): 1148-59.
  35. Magerl, C., et al., H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. Hum Pathol, 2010. 41(2): 181-9.
  36. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012. 12(4): p. 252-64.
  37. Essand, M., Virotherapy of neuroendocrine tumors. Neuroendocrinology, 2013. 97(1): 26-34.
  38. Ramachandran, M., et al., An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors. Mol Ther, 2013. 21(11): 2008-18.
  39. Galon, J., et al., Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol, 2014. 232(2): 199-209.
  40. Cidon, E.U., New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future
  41. NCT02075606, Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients (CALM-NET). 2017 A service of the U.S. National Institutes of Health: ClinicalTrials.gov
  42. Amorim GM, Quintella D, Cuzzi T , Rodrigues R, Ramos-e-Silva M Case Rep Dermatol. 2015 Sep-Dec; 7(3): 263–274
  43. Jedrych J, Busam K, Pulitzer K, Pulitzer M: Cutaneous metastases as an initial manifestation of visceral well-differentiated neuroendocrine tumor: a report of four cases and review of literature. J Cutan Pathol 2014, 41:113–122.
  44. Wang SM, Ye M, Ni SM: Multiple scalp metastases from colonic neuroendocrine carcinoma: case report and literature review. BMC Cancer 2014,14: 305.
Σχετικές Εργασίες – Relative Papers

Online ISSN 1011-6583

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
• Chemical Abstracts

• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Articles published in this Journal are Indexed or Abstracted in:
• Chemical Abstracts
• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Τι είναι η Review of Clinical Pharmacology and Pharmacokinetics-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς
What is Review of Clinical Pharmacology and Pharmacokinetics-International Edition-Instrunctions to Authors

Άρθρα Δημοσιευμένα στην Review of Clinical Pharmacology and Pharmacokinetics-Διεθνής Έκδοση
Articles Published in Review of Clinical Pharmacology and Pharmacokinetics-International Edition

Συντακτικη Επιτροπή-Editorial Board

Bookmark the permalink.

Comments are closed.